Last checked at 18 Nov 2014 07:00
18 November 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Appointment of a Non-Executive Director
Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed, with immediate effect, Jean-Yves Pavée as a Non-Executive Director; nominated by Abbott (NYSE: ABT).
Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott's Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. He joined Abbott in 1992.
Peter Jensen Chairman of Allergy Therapeutics commented:
"We are delighted towelcome Jean-Yves to the Board. He brings extensive industry experience, which will be invaluable toour Company as we continue to execute our global strategy."
Additional information regarding Jean-Yves Pavée:
Full name and age: Jean-Yves Frédéric Georges André Pavée-Callu, aged 51
There are no further disclosures required under Schedule Two paragraph (g) of the AIM rules.
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
Peel Hunt LLP | +44 (0) 20 7418 8900 |
James Steel | |
Clare Terlouw | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell |
Note to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. Ithas a growing business achieving revenue in thelast financial yearof £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into theEmerging markets